Metabolic-imaging of human glioblastoma live tumors: A new precision-medicine approach to predict tumor treatment response early

Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 12

Published: Sept. 5, 2022

Glioblastoma (GB) is the most severe form of brain cancer, with a 12-15 month median survival. Surgical resection, temozolomide (TMZ) treatment, and radiotherapy remain primary therapeutic options for GB, no new therapies have been introduced in recent years. This standstill primarily due to preclinical approaches that do not fully respect complexity GB cell biology fail test efficiently anti-cancer treatments. Therefore, better treatment screening are needed. In this study, we developed novel functional precision medicine approach response anticancer treatments organoids derived from resected tumors glioblastoma patients.GB were grown short period time prevent any genetic morphological evolution divergence tumor origin. We chose metabolic imaging by NAD(P)H fluorescence lifetime microscopy (FLIM) predict early non-invasively ex-vivo responses organoids. TMZ was used as benchmark drug validate approach. Whole-transcriptome whole-exome analyses performed characterize cases stratification.Our completed within one week after surgery two groups Responder Non-Responder identified. FLIM-based stratification well reflected at molecular level, confirming validity our approach, highlighting also target genes associated identifying 17-gene signature The number MGMT gene promoter methylated higher responsive group, expected, however, some non-methylated turned out be nevertheless TMZ, suggesting procedure could synergistic classical methylation biomarker.For first time, on live Unlike other approaches, patient-tailored an stage culturing animal involvement minimal tampering original cytoarchitecture. can exploited range clinical laboratory settings improve management patients implemented cancers well.

Language: Английский

---

Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma

Pharmaceuticals, Journal Year: 2023, Volume and Issue: 16(6), P. 793 - 793

Published: May 26, 2023

Despite decades of research and numerous clinical trials, the prognosis patients diagnosed with glioblastoma (GBM) remains dire median observed survival at 8 months. There is a critical need for novel treatments GBM, which most common malignant primary brain tumor. Major advances in cancer therapeutics such as immune checkpoint inhibitors chimeric antigen receptor (CAR) T-cell therapy have not yet led to improved outcomes GBM. Conventional surgery followed by chemoradiation or without tumor treating fields standard care. One many approaches GBM currently being explored viral therapies. These typically work selectively lysing target neoplastic cells, called oncolysis, targeted delivery therapeutic transgene via vector. In this review, we discuss underlying mechanisms action describe both recent current human trials using these viruses an emphasis on promising that may ultimately break field's stagnant paradigm.

Language: Английский

---

Exploring Monocytes-Macrophages in Immune Microenvironment of Glioblastoma for the Design of Novel Therapeutic Strategies

Brain Sciences, Journal Year: 2023, Volume and Issue: 13(4), P. 542 - 542

Published: March 24, 2023

Gliomas are primary malignant brain tumors. These tumors seem to be more and frequent, not only because of a true increase in their incidence, but also due the life expectancy general population. Among gliomas, gliomas specifically glioblastomas (GBM) challenge diagnosis treatment. There few effective therapies for these tumors, patients with GBM fare poorly, even after aggressive surgery, chemotherapy, radiation. Over last decade, it is now appreciated that composed numerous distinct tumoral non-tumoral cell populations, which could each influence overall tumor biology response therapies. Monocytes have been proved actively participate growth, giving rise support tumor-associated macrophages (TAMs). In GBM, TAMs represent up one half mass cells, including both infiltrating resident microglia. Infiltrating macrophages/monocytes constituted ~ 85% total TAM population, they immune functions, can release wide array growth factors cytokines those produced by non-tumor cells from microenvironment (TME). A brief review literature shows this population has increasingly studied TME understand its role progression therapeutic resistance. Through knowledge protumoral function, development strategies employ recruitment as well modulation immunological phenotype, eradication harnessed benefit. This revision aims summarize localization niches special focus on origin functions resistance conventional experimental treatments. Moreover, recent advances targeting new cellular based monocyte/macrophages eradicate discussed complementary therapeutics.

Language: Английский

---

Structural characterization and in silico evaluation of bioactive compounds from Rhus cotinus (Syn. Cotinus coggygria) roots as potential EGFR inhibitors for brain Cancer

Results in Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 102101 - 102101

Published: Feb. 1, 2025

Language: Английский

---

Transcriptome‐wide analysis of circRNA and RBP profiles and their molecular relevance for GBM

Molecular Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 26, 2025

Language: Английский

---